Dexcom

DXCM · Health Care · Market cap $28.4B

Q1 FY26 Mar 31, 2026 reported Apr 30, 2026

Revenue$1.2B +15% year over year

Gross profit$0.8B

Operating profit$0.3B

Net profit$0.2B 17% margin

Numbers and detail

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.2	100%	+15%
United States	0.8	67%	+11%
International	0.4	33%	+26%
Cost of revenue	−0.4	33%
Gross profit	0.8	63% margin	+6pp
Research & development	−0.1	12%	−2pp
Sales & marketing	−0.1	7%	+0pp
SG&A	−0.3	29%	−1pp
Operating profit	0.3	21% margin	+9pp
Tax	−0.1
Net profit	0.2	17%	+7pp

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1	100%	+12%
United States	0.8	80%
International	0.3	30%
Cost of revenue	−0.4	40%
Gross profit	0.6	57% margin	−4pp
Research & development	−0.1	14%	−1pp
Sales & marketing	−0.1	7%	+0pp
SG&A	−0.3	30%	−5pp
Operating profit	0.1	13% margin	+2pp
Net profit	0.1	10%	−6pp

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26	Mar 31, 2026	Apr 30, 2026	$1.2B	+15%	25%	$0.2B	17%
Q1 FY25	Jan 1 – Mar 31, 2025	May 1, 2025	$1B	+12%	10%	$0.1B	10%